Prepared by:
Southern California Evidence-Based Practice Center
Mary Hardy, M.D.
Principal Investigator
Ian Coulter, Ph.D.
Sally C. Morton, Ph.D.
Joya Favreau, M.D.
Swamy Venuturupalli, M.D.
Francesco Chiappelli, Ph.D.
Frederico Rossi, M.D.
Greg Orshansky, MD
Lara K. Jungvig, B.A.
Elizabeth A. Roth, M.A.
Marika J. Suttorp, M.S.
Paul Shekelle, M.D., Ph.D.
Investigators
File Name Description Software Version File Size _______________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 2002 58KB 7 pages Contents: Cover, Title Page, Preface, Structured Abstract _______________________________________________________________________________________________________ 02conts.doc Microsoft Word® Document MS Word® 2002 33KB 3 pages Contents: Table of Contents _______________________________________________________________________________________________________ 03summ.doc Microsoft Word® Document MS Word® 2002 57KB 4 pages Contents: Summary: Overview, Reporting the Evidence, Methodology, Findings, Future Research _______________________________________________________________________________________________________ 04chap1.doc Microsoft Word® Document MS Word® 2002 86KB 10 pages Contents: Chapter 1. Introduction: Purpose, Scope of Work, S-Adenosyl-L-Methionine, Depression, Osteoarthritis, Liver Disease, Summary _______________________________________________________________________________________________________ 05chap2.doc Microsoft Word® Document MS Word® 2002 123KB 9 pages Contents: Chapter 2. Methods: Scope of Work, Objectives, Literature Search Design, Evaluation of Evidence, Selection of Studies for Meta-Analysis, Table 1. Biomedical databases searched, Table 2. Pharmaceutical and other biomedical databases searched, Table 3. Additional search terms for SAMe, Table 4. Summary of search strategy, Figure 1. Studies considered for meta-analysis _______________________________________________________________________________________________________ 06chap3.doc Microsoft Word® Document MS Word® 2002 835KB 38 pages Contents: Chapter 3. Results: Description of Evidence, Analysis of Depression Studies, Analysis of Osteoarthritis Studies, Analysis of Liver Disease Studies, Side Effects, Comparison With Results of Other Systematic Reviews, Limitations of the Review; Table 5. SAMe versus placebo studies risk ratios; Table 6. SAMe versus placebo: depression effect size, pooled analysis; Table 7. SAMe versus other drugs risk ratios pooled analyses; Table 8. SAMe versus other drugs depression effect size pooled analysis; Table 9. Publication bias test results; Table 10. SAMe versus placebo: OA, pooled analysis; Table 11. Study distribution by NSAID dose and SAMe dose; Table 12. SAMe versus NSAID pooled analysis; Table 13. Effect sizes for interventions excluded from SAMe versus placebo pooled analysis (pruritus); Table 14. SAMe versus placebo pooled analysis (pruritus); Table 15. SAMe versus ursodeoxycholic acid (pruritus); Table 16. Effect sizes for interventions excluded from SAMe versus placebo pooled analysis (serum bilirubin); Table 17. SAMe versus placebo pooled analysis (serum bilirubin); Table 18. SAMe versus ursodeoxycholic acid (serum bilirubin); Table 19. SAMe versus placebo pooled analysis for a mix of chronic and acute patients (pruritus); Table 20. SAMe versus placebo pooled analysis for cholestasis in patients with chronic liver disease (serum bilirubin); Table 21. SAMe versus placebo effect sizes for patients with acute liver disease (serum bilirubin); Table 22. SAMe versus prednisolone effect size for patients with chronic liver eisease (serum bilirubin); Table 23: Distribution of Jadad score in other liver studies; Table 24. SAMe manufacturer support by disease state; Figure 2. Depression Outcome: Continuous Hamilton Score: SAMe Versus Placebo; Figure 3. Depression Outcome: Number Greater Than 50%: SAMe Versus Other Drugs; Figure 4. Depression Outcome: Number Greater Than 25%: SAMe Versus Other Drugs; Figure 5. Depression Outcome: Continuous Hamilton Score: SAMe Versus Other Drugs; Figure 6. Depression Outcome: Continuous Hamilton: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 7. Depression Outcome: Continuous Hamilton: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 8. Depression Outcome: Number Greater Than 50%: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 9. Depression Outcome: Number Greater Than 25%: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 10. OA Outcome: Pain at Four Weeks Follow-up: SAMe (Medium/High Dose) Versus NSAIDS; Figure 11. OA Outcome: Pain at Four Weeks Follow-up: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 12. Cholestasis of Pregnancy Outcome: Pruritus: SAMe Versus Placebo; Figure 13. Cholestasis of Pregnancy Outcome: Pruritus: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 14. Cholestasis of Pregnancy Outcome: Serum Bilirubin: SAMe Versus Placebo; Figure 15. Cholestasis of Pregnancy Outcome: Serum Bilirubin: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 16. Cholestasis Outcome: Pruritus: SAMe Versus Placebo; Figure 17. Cholestasis Outcome: Pruritus: Begg's Funnel Plot with Pseudo 95% Confidence Limits; Figure 18. Cholestasis Outcome: Serum Bilirubin: SAMe Versus Placebo; Figure 19. Cholestasis Outcome: Serum Bilirubin: Begg's Funnel Plot with Pseudo 95% Confidence Limits _______________________________________________________________________________________________________ 07chap4.doc Microsoft Word® Document MS Word® 2002 55KB 3 pages Contents: Chapter 4. Future Research _______________________________________________________________________________________________________ 08refs.doc Microsoft Word® Document MS Word® 2002 93KB 9 pages Contents: References _______________________________________________________________________________________________________ 09etbI.doc Microsoft Word® Document MS Word® 2002 309KB 23 pages Contents: Evidence Table I. SAMe for Treatment of Depression _______________________________________________________________________________________________________ 10etbII.doc Microsoft Word® Document MS Word® 2002 95KB 7 pages Contents: Evidence Table II. SAMe for Treatment of Osteoarthritis _______________________________________________________________________________________________________ 11etbIII.doc Microsoft Word® Document MS Word® 2002 86KB 6 pages Contents: Evidence Table III. SAMe for Treatment of Cholestasis of Pregnancy _______________________________________________________________________________________________________ 12etbIV.doc Microsoft Word® Document MS Word® 2002 97KB 7 pages Contents: Evidence Table IV. SAMe for Treatment of Cholestasis (Liver Disease) _______________________________________________________________________________________________________ 13etbV.doc Microsoft Word® Document MS Word® 2002 176KB 11 pages Contents: Evidence Table V. SAMe for Treatment of Liver Disease (General) _______________________________________________________________________________________________________ 14biblio.doc Microsoft Word® Document MS Word® 2002 140KB 14 pages Contents: Bibliography _______________________________________________________________________________________________________ 15appa.doc Microsoft Word® Document MS Word® 2002 63KB 10 pages Contents: Appendix A. Search Methods _______________________________________________________________________________________________________ 16appb.doc Microsoft Word® Document MS Word® 2002 21KB 1 page Contents: Appendix B. Articles not Obtainable _______________________________________________________________________________________________________ 17appc.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Appendix C. Article Screening Form _______________________________________________________________________________________________________ 18appd.doc Microsoft Word® Document MS Word® 2002 271KB 8 pages Contents: Appendix D. Quality Review Form _______________________________________________________________________________________________________ 19appe.doc Microsoft Word® Document MS Word® 2002 32KB 1 page Contents: Appendix E. The Jadad Score _______________________________________________________________________________________________________ 20appf.doc Microsoft Word® Document MS Word® 2002 178KB 7 pages Contents: Appendix F. Side Effects _______________________________________________________________________________________________________ 21appg.doc Microsoft Word® Document MS Word® 2002 241KB 8 pages Contents: Appendix G. Support Table _______________________________________________________________________________________________________ 22apph.doc Microsoft Word® Document MS Word® 2002 21KB 1 page Contents: Appendix H. Abbreviations for Outcomes in the Evidence Tables _______________________________________________________________________________________________________ 23appi.doc Microsoft Word® Document MS Word® 2002 92KB 6 pages Contents: Appendix I. Authors' Response to Reviewer Comments _______________________________________________________________________________________________________ 24appj.doc Microsoft Word® Document MS Word® 2002 47KB 4 pages Contents: Appendix J. Acknowledgments _______________________________________________________________________________________________________
AHRQ Publication No. 02-E034
Current as of October 2002
Internet Citation:
S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. File Inventory, Evidence Report/Technology Assessment Number 64. AHRQ Publication No. 02-E034, October 2002. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/sameinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services